Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KZRNASDAQ:LVTXNASDAQ:RVPHNASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZRKezar Life Sciences$4.52+1.3%$4.29$3.62▼$9.18$32.58M0.5856,498 shs63,758 shsLVTXLAVA Therapeutics$1.31-2.2%$1.29$0.85▼$2.39$35.25M0.48156,071 shs15,523 shsRVPHReviva Pharmaceuticals$0.70+4.1%$0.84$0.49▼$4.28$31.50M0.111.16 million shs409,168 shsXTLBXTL Biopharmaceuticals$1.14+0.9%$3.99$0.92▼$3.05$6.65M1.0918,434 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZRKezar Life Sciences+1.35%-1.53%+12.72%-23.26%-30.98%LVTXLAVA Therapeutics+1.08%0.00%-0.76%+0.77%-32.82%RVPHReviva Pharmaceuticals+4.12%-3.37%-29.11%-32.52%-48.77%XTLBXTL Biopharmaceuticals-13.31%-10.94%+5.56%-2.56%-54.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKZRKezar Life Sciences4.2298 of 5 stars3.25.00.04.60.62.50.6LVTXLAVA Therapeutics1.7005 of 5 stars3.05.00.00.00.00.00.0RVPHReviva Pharmaceuticals2.1619 of 5 stars3.61.00.00.00.63.30.6XTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKZRKezar Life Sciences 2.33Hold$39.50773.89% UpsideLVTXLAVA Therapeutics 2.00Hold$3.17141.73% UpsideRVPHReviva Pharmaceuticals 3.29Buy$9.001,182.42% UpsideXTLBXTL Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XTLB, KZR, RVPH, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/20/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $3.005/15/2025LVTXLAVA TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/24/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/1/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.003/31/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.50(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKZRKezar Life Sciences$7M4.72N/AN/A$16.02 per share0.28LVTXLAVA Therapeutics$11.98M2.88N/AN/A$1.06 per share1.24RVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/AXTLBXTL Biopharmaceuticals$450K13.81N/AN/A$1.00 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.04N/AN/AN/AN/A-86.38%-34.12%8/19/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)XTLBXTL Biopharmaceuticals-$1.03MN/A0.00∞N/AN/AN/AN/AN/ALatest XTLB, KZR, RVPH, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RVPHReviva Pharmaceuticals-$0.21-$0.13+$0.08-$0.13N/AN/A5/14/2025Q1 2025LVTXLAVA Therapeutics-$0.37-$0.13+$0.24-$0.13N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A3/31/2025Q4 2024RVPHReviva Pharmaceuticals-$0.22-$0.15+$0.07-$0.15N/AN/A3/28/2025Q4 2024LVTXLAVA Therapeutics-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 million3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKZRKezar Life SciencesN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKZRKezar Life Sciences0.047.097.09LVTXLAVA TherapeuticsN/A6.736.73RVPHReviva PharmaceuticalsN/A0.540.54XTLBXTL BiopharmaceuticalsN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKZRKezar Life Sciences67.90%LVTXLAVA TherapeuticsN/ARVPHReviva Pharmaceuticals63.18%XTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipKZRKezar Life Sciences10.40%LVTXLAVA Therapeutics9.50%RVPHReviva Pharmaceuticals27.18%XTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableRVPHReviva Pharmaceuticals546.74 million34.04 millionOptionableXTLBXTL BiopharmaceuticalsN/A5.45 million3.87 millionNot OptionableXTLB, KZR, RVPH, and LVTX HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comXTL Biopharmaceuticals Reports Financial Results Amid Regional UnrestDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional ChallengesDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock, Short Interest ReportNovember 5, 2024 | benzinga.comXTL Biopharmaceuticals Ltd (XTLB)September 5, 2024 | investing.comXTL Biopharmaceuticals Ltd XTLBAugust 22, 2024 | morningstar.comXTL Biopharmaceuticals acquires AI firm Social ProxyAugust 16, 2024 | uk.investing.comXTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionAugust 14, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. (XTLB.TA)July 22, 2024 | finance.yahoo.comXTL Entered Definitive Agreement to Acquire The Social ProxyJune 5, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. ADRApril 26, 2024 | wsj.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsMarch 20, 2024 | msn.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comCrude Oil Surges 2%; Signet Jewelers Shares Spike HigherMarch 20, 2024 | markets.businessinsider.comXTL To Aquire The Social ProxyMarch 20, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd ADR (XTLB)February 17, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTLB, KZR, RVPH, and LVTX Company DescriptionsKezar Life Sciences NASDAQ:KZR$4.52 +0.06 (+1.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.51 0.00 (-0.11%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.LAVA Therapeutics NASDAQ:LVTX$1.31 -0.03 (-2.24%) Closing price 06/20/2025 03:56 PM EasternExtended Trading$1.36 +0.04 (+3.44%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Reviva Pharmaceuticals NASDAQ:RVPH$0.70 +0.03 (+4.12%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.68 -0.02 (-2.39%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.XTL Biopharmaceuticals NASDAQ:XTLBXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
